ABSTRACT
INTRODUCTION C
LASSIC STUDIES of the adult mammalian central nervous system (CNS) have demonstrated that regeneration is limited in response to insult and injury (Ramon y Cajal, 1928) . This poses a significant challenge for researchers in their search for a cure for spinal cord injury (SCI). The long-held concept that the CNS had a finite number of neurons has been repudiated by observations of neurogenesis in the adult hippocampus and subventricular zone (Eriksson et al., 1998; Lois and Alvarez-Buylla, 1993) . Much attention recently has focused on the therapeutic potential of CNS stem cells, both endogenous and exogenously grafted, to facilitate spinal cord repair. While such approaches once seemed straightforward, they have proved to be exquisitely complex. Post-transplantation lineage restriction (Cao et al., 2002a; Reier, 2004) as well as variable host responses to the engrafted cell population (Ourednik and Ourednik, 2004a,b) significantly impacts the therapeutic outcome of stem cell therapy for SCI.
The goal of developing stem cell-based transplantation therapy for SCI can be broadly categorized into four main objectives: oligodendroglial replacement/functional remyelination, neural replacement/gray matter reconstitution, providing a permissive substrate for axonal regeneration, and/or neuroprotection. The varied stem cell sources, transplant methodologies, and injury paradigms employed make it difficult to effectively compare results and conclusions between studies. A critical evaluation of both success and failure is an essential first step in developing sound translational approaches for the therapeutic application of stem cell-based treatment of SCI.
This review will summarize the current knowledge related to the transplantation of CNS-derived (from embryonic stem [ES] cells, fetal, neonatal, and adult) and non-neural stem cells for the treatment of experimental SCI. We will focus on non-immortalized therapeutic cell populations, as results from grafting immortalized cells in SCI have been previously reviewed (Whittemore and Onifer, 2000) . Table 1 pays particular attention to several issues that we believe may explain both similarities and differences in the major conclusions drawn from results obtained from studies that, on the surface, appear to be methodologically comparable. These include variations in the origin of the stem cells, lesion models, and methods used to determine the functional contribution of the engrafted cells. The first half of this review will focus on the potential of neural-derived stem cells with respect to remyelination, neuronal replacement, and neuroprotection/regeneration in experimental models of SCI. The latter half of the review will evaluate the potential of non-CNS-derived stem and progenitor cells and their therapeutic potential in SCI. The ultimate goal of this review will be to clarify existing data toward establishing comparable therapeutic protocols for the successful treatment of SCI.
NEURAL STEM CELL-MEDIATED REMYELINATION IN SCI
Demyelination contributes to dysfunction of the traumatically injured spinal cord in both humans and experimental animals (Blight, 2002; Bunge et al., 1993; Cao et al., 2005a; Gledhill et al., 1973; Guest et al., 2005; Waxman, 1989) . Therefore, remyelination of demyelinated, but otherwise intact axons represents an important repair strategy for the treatment of SCI (Blight, 2002) . The potential for oligodendrocytic differentiation and remyelination by engrafted stem cells has been most clearly and consistently demonstrated following transplantation into the demyelinated/dysmyelinated spinal cord. While undifferentiated ES cells do not respond appropriately to environmental cues and often develop into heterotopias or tumors (Bjorklund, 2000; Reubinoff et al., 2000; Thomson et al., 1998) , both mouse (Brustle et al., 1999; Liu et al., 2000) and human ) ES cell-derived glial precursors exhibit robust remyelination following transplantation into myelin-deficient mice. Transplantation of these precursor cells into the dorsal column of myelin-deficient rat or shiverer mouse spinal cord showed that the engrafted cells migrate widely in the host CNS. Some cells terminally differentiated into mature oligodendrocytes, ensheathed demyelinated axons, and formed myelin (Brustle et al., 1999; Liu et al., 2000; Nistor et al., 2005) .
In addition to ES-derived glial precursors, embryonic neural stem cells (NSCs) derived from the rat striatum and midbrain readily remyelinate axons in the myelindeficient rat spinal cord (Hammang et al., 1997) . Likewise, embryonic mouse NSCs remyelinate chemically demeylinated axons in the adult rat spinal cord (Liu et al., 2000) . Both intraspinal application of human brainderived NSCs ) and intravenous injection of adult mouse SVZ NSCs (Pluchino et al., 2003) results in extensive remyelination of focal ethidium bromide (EB)-demyelinated and experimental autoimmune encephalomyelitic lesions, respectively. In vitro induction of NSC into oligodendrocyte precursor cells (OPCs) prior to transplantation further enhances their differentiation into oligodendrocytes capable of successful remyelination following engraftment into the de/dysmyelinated spinal cord. Transplantation of OPCs derived from NSCs following treatment with conditioned medium from the B104 neuroblastoma cell line achieved significantly larger areas of myelination compared with that obtained from undifferentiated NSCs following transplantation into the spinal cord of the myelin-deficient rat or EB-demyelinated spinal cord (Smith and Blakemore, 2000) .
In addition to deriving glial precursors in vitro from multipotent neural and embryonic stem cells, glial precursors can be obtained directly from embryonic tissue. These cells have been successfully isolated and propagated from the developing spinal cord (Mujtaba et al., 1999; Mayer-Proschel, 1997), brain (Ben-Hur et al., 1998) , and optic nerve (Barres et al., 1992) . Neonatal brain-derived glial precursors differentiate into myelinating cells and appear to remyelinate demyelinated axons after transplantation into the EB-or mouse hepatitis virus (MHV)-lesioned spinal cord (Keirstead et al., 1999a; Totoiu et al., 2004) . In addition to oligodendrocyte differentiation, Keirstead et al. (1999) also showed significant Schwann cell differentiation by rat brain precursors engrafted into EB lesions. Using the same lesion model, Akiyama et al. (2001) CsA, cyclosporine A; EAE, experimental autoimmune encephalomyelitis; BBB, Basso-Beattie-Breshnahan; NSC, neural stem cell; NRP, neuronal-restricted precursor cells; tcMMEP, transcranial magnetic neuronal-restricted precursor cells; tcMMEP, transcranial magnetic motor evoked potentials; EB-X, ethidium bromide x-irradiation; GRP, glial-restricted precursor cells; MP, methylprednisolone; MHV, murine hepatitis virus.
sions likely accounts for this unmasked plasticity of engrafted CNS-derived precursors (Blakemore, 2005) . Several distinct cell types can mediate remyelination in a variety of demyelinating and dysmyelinating models of SCI. Regardless of whether ES- (Brustle et al., 1999; Liu et al., 2000; Nistor et al., 2005) , embryonic- (Hammang et al., 1997) , neonatal- (Totoiu et al., 2004) , or adult-derived (Pluchino et al., 2003; Zhang et al., 1999) grafts were placed in a myelin-deficient recipient (transgenic rat, shiverer mouse, multiple sclerosis models), significant remyelination was consistently observed. Perhaps due to the dense arrangement of dys/demyelinated axons amenable to remyelination, these models provide an environment favorable to oligodendrocyte differentiation and remyelination. Additionally, in all of the studies where brain-and ES cell-derived precursor cells were transplanted into the focal demyelinated dorsal column Keirstead et al., 1999a; Liu et al., 2000; Smith et al., 2000) , the grafts differentiated with a myelinating phenotype. More studies employing focal demyelination in areas outside the dorsal column will be necessary to determine whether the area the cells were placed into rather the origin/homogeneity of the transplant defines their differentiated fate.
Experiments attempting remyelination by engrafted cells in traumatic models of SCI revealed quite heterogeneous results. McDonald et al. (1999) have shown significant oligodendrocytic differentiation and locomotor improvement following transplantation of neuralized murine ES cells into the contused spinal cord McDonald et al., 1999) . However, using a comparable experimental setting and the same ES cell line, Howard et al. (2005) could not replicate these findings. Different in vitro protocols to partially differentiate the ES cells prior to transplantation might have accounted for the contradictory results. Grafting human ES cells differentiated to near homogeneity to a more mature oligodendrocyte phenotype (Ͼ90% RIP ϩ ), Keirstead et al. (2005) also observed myelination and partial hindlimb locomotor recovery, although that functional recovery could not be unequivocally shown to result from remyelination. More limited or completely absent oligodendrocytic differentiation has been observed following engraftment of both embryonic and adult-derived NSCs transplanted into traumatic SCI models Chow et al., 2000; Cummings et al., 2005; Hasegawa et al., 2004; Iwanami et al., 2005; Ogawa et al., 2002; Vroemen et al., 2003) . Reported locomotor improvement following absent or minimal graft differentiation is hard to reconcile as appropriate transplant controls were not thoroughly conducted in some of these studies (Cummings et al., 2005; Iwanami et al., 2005; Ogawa et al., 2002) . Additionally, the use of species inappropriate locomotor tests are difficult to unambiguously interpret (Cummings et al., 2005) . Recently, Hofstetter et al. (2005) showed that 17% of adult spinal cord-derived NSCs engrafted into a low thoracic weight drop injury expressed the oligodendrocyte lineage marker RIP. The proportion of RIP ϩ cells that had terminally differentiated with more mature oligodendrocyte phenotype, however, was not reported. The absence of increased myelination at the injury site following NSC engraftment indicates that apparent oligodendrocyte differentiation and remyelination was limited. Glial restricted A2B5 ϩ /NG2 precursor cells (GRPs) isolated from the embryonic spinal cord either differentiate into astrocytes or remain undifferentiated after transplantation into the traumatically injured spinal cord (Cao et al., 2005b; Han et al., 2004; Hill et al., 2004) , with only small numbers of oligodendrocytes arising from engrafted precursor cell populations. These studies seem to contradict findings by Keirstead et al. (1999) and Totoiu et al. (2004) , who demonstrated widespread remyelination by engrafted glial precursors. However, besides employing a different injury paradigm (demyelination versus traumatic), the latter studies used neonatal brain-derived PS-NCAM ϩ cells or unpurified striatal grafts, respectively. More recently, Cao et al. (2005b) showed that engrafting GRPs genetically modified to express D15A, a multi-neurotrophin with both BDNF and NT3 activities, into the contused thoracic spinal cord facilitated oligodendrocyte differentiation, conduction through the spinal cord, and locomotor improvement.
Collectively, these results suggest that, unlike de/dysmyelinated lesions, the microenvironment of the traumatically injured spinal cord restricts oligodendrocyte differentiation of engrafted cells. The overriding question is what factors in the injured spinal cord may be responsible for this inhibition. Studies to identify possible inhibitors of oligodendrocyte differentiation in the traumatically injured spinal cord are a critical first step in enhancing stem cell-mediated remyelination. Once identified, it is likely that both manipulations of engrafted precursor cells to be unresponsive to the inhibitors and/or modification of the microenvironment in the injured spinal cord, as well as the concomitant induction of expression of factors predicted to enhance remyelination by engrafted cells may be needed to increase the functional remyelination from transplanted cells. Consistent with this prediction, the combinatorial delivery of sonic hedgehog with engraftment of OPCs was found to both increase the number of OPCs in dorsal explant cultures and result in functional recovery (both electrophysiological and behavioral) in the contusion-injured spinal cord (Bambakidis and Miller, 2004 
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Ȩ and increased oligodendrocyte differentiation concomitant with an increase in oligodendrocyte remyelination following transplantation into a contusion SCI (Hofstetter et al., 2005) . These data suggest that alteration of intrinsic NSC properties can induce preferential oligodendrocyte differentiation even in the unfavorable environment of the injured spinal cord. Understanding the mechanisms of oligodendrocyte differentiation in the injured spinal cord will be critical to the further development of therapeutic remyelination strategies based on stem cell transplantation.
NEURONAL REPLACEMENT IN THE INJURED SPINAL CORD
The degree to which neuronal loss contributes to the functional deficits observed following SCI is not well known. It is obvious that motor neuron death, especially in the cervical and lumbar enlargements, can contribute to locomotor dysfunction following SCI. Therefore, stem cell-based motor neuronal replacement may be an important strategy facilitating recovery. However, the majority of studies outlined in Table 1 employing ES, embryonic, or adult-derived NSCs transplantation into the injured spinal cord have observed primarily glial differentiation, regardless of the injury model used. Embryonic pluripotent NSCs engrafted into compressive (Ogawa et al., 2002) , hemisected (Chow et al., 2000) , and contused ) models of traumatic SCI, as well as atraumatic, excitotoxic (Magnuson et al., 2001) , and focal ischemic Enzmann et al., 2005) injury paradigms, all differentiate predominantly into astrocytes. Consistent with these results, NSCs isolated from the adult CNS are restricted almost exclusively to a glial fate following engraftment into a dorsal hemisection (Vroemen et al., 2003) or thoracic weight-drop (Hofstetter et al., 2005) injury. While all of these studies confirmed the multipotentiality of engrafted cells in vitro prior to engraftment, the dramatic shift towards a glial phenotype in vivo suggests that the injured spinal cord expresses factors that favor glial differentiation of multipotent NSCs. Moreover, the contused spinal cord is an environment that restricts neuronal differentiation (Cao et al., 2002b) . Although limited neuronal differentiation was observed in some studies (Chow et al., 2000; Hofstetter et al., 2005; McDonald et al., 1999; Ogawa et al., 2002) , no study to date has demonstrated large-scale neuronal differentiation by engrafted stem cells in the injured spinal cord. Consequently, neuronal replacement following SCI will likely require transplantation of cells more committed to a neuronal lineage and/or modification of the host environment or the response of engrafted cells to local signals following injury.
One example of the success of such an approach is the finding that in vitro induction of NSCs into cholinergic motor neurons may be necessary for successful motor replacement after SCI (Gao et al., 2005; Harper et al., 2004; Kerr et al., 2003a; Wu et al., 2002) . Further, several groups have developed protocols to generate cholinergic neurons from murine ES cells (Renoncourt et al., 1998; Wichterle et al., 2002) and human NSCs (Wu et al., 2002) . Following engraftment into the adult spinal cord with motor neuronal loss induced by sciatic nerve crush at P1, human NSC-derived cholinergic neurons differentiate into phenotypically mature motor neurons (Gao et al., 2005) . Most importantly, these transplant-derived motor neurons send axons that pass through the ventral root and sciatic nerve to form neuromuscular junctions with their peripheral muscle targets. Furthermore, this new cholinergic innervation correlates with partial improvement of motor function. In other studies, engrafted ES-derived cholinergic motor neurons were also observed in the rat spinal cord with a neuroadapted sindbis virus-induced motor neuronopathy (Harper et al., 2004; Kerr et al., 2003a) . These data suggest that transplantation of ES-or NSC-derived cholinergic neurons can replace lost motor neurons after both peripheral and central insult and at least partially restore motor function. Whether such methodologies can lead to successful motor neuron replacement in the traumatically injured spinal cord remains to be determined.
In addition to motor neuron replacement, another strategy employing transplantation of neurons into the injured spinal cord is to facilitate the activation of spinal cord circuitry below the level of injury, resulting in the enhancement of segmental reflex arcs and the subsequent improvement of locomotor function (Pearson, 2001 ). Embryonic raphe cells transplanted distal to the lesion site into the spinal cord of adult rats can reinnervate specific targets, perhaps the central pattern generator in the lumbar spinal cord (Cazalets et al., 1995; Magnuson et al., 1999) , resulting in the restoration of neurotransmitter receptor densities, partial hindlimb weight support, and enhanced locomotor activity on a treadmill (Ribotta et al., 1998; Ribotta et al., 2000) . Transplantation of ES-or NSC-derived neurons into the injured spinal cord may be able to provide a similar therapeutic benefit, but studies examining this possibility need to be completed before these neuronal replacement approaches become a translational reality.
In summary, naive pluripotent NSCs fail to differentiate into motor neurons after transplantation into adult spinal cord, presumably because of restrictive environmental cues Chow et al., 2000; Fricker et al., 1999; Shihabuddin et al., 2000; Vroemen et al., ENZMANN ET AL. 2003) . NRPs can differentiate into neurons after transplantation into the uninjured adult spinal cord, but their neuronal differentiation is inhibited in the injured spinal cord (Cao et al., 2002b) . Another study that employed mixed NRP-GRP grafts to facilitate differentiation in the injured thoracic SC, reported locomotor improvement (Mitsui et al., 2005) . Unfortunately, the lack of transplant controls in that study makes interpretation of these results problematic. Induction of engrafted cells along neuronal lineages, combined with modification of the environment in the injured spinal cord to favor neuronal differentiation and/or survival of engrafted cells, are likely to be necessary for a successful neuronal replacement by means of stem cells. BMPs are likely candidate molecules as in vitro they facilitate astrocyte differentiation from pluripotent stem cells (Grinspan et al., 2005) and block neuronal differentiation (Krizhanovsky and Ben-Arie, 2005) . However, attempts to suppress BMP action in both the ischemic and traumatic spinal cord by grafting noggin-expressing precursor cells significantly increased the size of the lesion (Enzmann et al., 2005) , highlighting the problems with attempts to globally alter signaling in the injured spinal cord.
Three studies have reported functional recovery (Cao et al., 2005a; Hofstetter et al., 2005; McDonald et al., 1999; Ogawa et al., 2002) , one reported no functional improvement (Magnuson et al., 2001) , and function was not assessed in three reports Chow et al., 2000; Vroemen et al., 2003) following ES or NSC transplantation into models of traumatic SCI. Mouse ES-derived NSCs enhanced locomotor functional recovery as assessed by Basso-Beattie-Breshnaham (BBB) scores following transplantation into the contused thoracic spinal cord (McDonald et al., 1999) . Since most engrafted cells (>40%) differentiated into oligodendrocytes and the deficits incurred after thoracic contusion injury are not the result of lost neurons (Magnuson et al., 1999) , the functional recovery was hypothesized to result from remyelination by engrafted ES cells. However, unequivocal proof that stem cell-mediated remyelination is sufficient to restore electrophysiological conduction of axons in vivo and that this functional restoration can lead to behavioral improvement has only been demonstrated in one study (Cao et al., 2005b) . Ogawa et al. (2002) also reported functional recovery as measured by a skilled reaching task-pellet retrieval test following transplantation of embryonic NSCs into the compressed C4 spinal cord. Some engrafted NSCs differentiated into neurons and formed synapses with host neurons. The authors propose that transplant-derived neurons may have aided in bypassing disrupted fibers and thus relayed signals in the dorsal column important for pellet retrieval behavior.
TROPHIC FACTORS AND PERMISSIVE SUBSTRATES
Neural stem and progenitor cells might improve the functional outcome after SCI by means other than their potential for lineage-specific differentiation. Recent experiments revealed that NSCs constitutively secrete GDNF, NGF, and BDNF (Llado et al., 2004; Lu et al., 2003) . That might explain some of the functional improvements seen after stem transplantation into the injured spinal cord, especially in the absence of a relevant graft differentiation. Hill et al. (2004) impressively showed that acutely transplanted GRPs both decreased astrocytic scarring and proteoglycan deposition 8 days after contusion and concomitantly led to an increased number of corticospinal tract (CST) axons. Most recently, Hofstetter et al. (2005) reported significant functional improvements in BBB locomotor and grid-walking behavior following transplantation of adult spinal cord-derived naive NSCs 1 week after low thoracic weight-drop SCI. As the majority of the graft displayed an astrocytic phenotype, the mechanism accounting for this functional recovery is unclear and not attributable to an increase in myelination. In that study, the authors also showed that NSC engraftment was associated with significantly increased allodynia in the unaffected forepaws. Furthermore, the degree of graft-induced local sprouting of calcitonine gene-related peptide (CGRP) fibers was directly correlated with the extent of astrocyte differentiation by engrafted cells and the development of allodynia-like symptoms. Ngn2 expression by engrafted NSCs virtually eliminated astrocyte differentiation and graft-induced allodynia, yet still resulted in significant functional improvement. These results are particularly important in light of the tendency for astrocytic differentiation by virtually all NSC types in the injured spinal cord. They further support the suggestion that optimal functional benefits with the fewest side-affects will result from the engraftment of stem cells which have been manipulated prior to engraftment to preferentially commit to a desired lineage. Thus, in addition to their potential to replace lost tissue after SCI, stem cells seem capable of facilitating host repair by secretion of growth factors and other mechanisms that await elucidation.
NON-NEURAL STEM AND PROGENITOR CELL TRANSPLANTATION IN SCI
After initial reports of in vivo transdifferentiation of engrafted mesodermal cells into neural cells (Brazelton et al., 2000; Mezey et al., 2000) , there has been an increase in the number of studies utilizing bone marrow STEM CELL TRANSPLANTATION THERAPY FOR SPINAL CORD REPAIR (BM), BM stromal cells, and umbilical cord blood transplantation in attempts to restore function after SCI (Table  1) . In many of the outlined studies, claims are made that BM does not require any in vitro manipulation to commit cells along a neural cell type prior to transplantation and therefore, transplant cell populations could be applied systemically. This is a remarkable possibility with virtually unlimited therapeutic potential. If corroborated, this homing aspect would be therapeutically important as intraspinal delivery methodologies commonly employed in the majority of stem cell transplantation approaches may additionally compromise the damaged tissue. In the following sections, we will give a concise overview of results obtained from recent studies utilizing these cell populations and realistically assess their therapeutic potential.
BONE MARROW AND HEMATOPOIETIC STEM CELL TRANSPLANTATION IN SCI
Results from studies using BM-derived cell populations in transplantation strategies have yielded interesting but complex results. For example, while transplantation of neither highly purified murine BM-side population (SP) (Castro et al., 2002) nor CD34 ϩ cells (Sasaki et al., 2001 ) resulted in any terminal cell differentiation, both xenogeneic (Sasaki et al., 2001 ) and allogeneic whole BM (Akiyama et al., 2002a ) differentiated primarily into Schwann cells and oligodendrocytes following engraftment into the EB-demyelinated dorsal column. The potential of CD34 ϩ cells is difficult to interpret, as the significance of CD34 as a marker for murine hematopoietic stem cell (HSC) is controversial (Verfaillie, 2002) and is suggested rather to decorate mature mast cells in the BM (Drew et al., 2002) . However, if BM stem cells indeed have the potential to cross germ layer restrictions, the SP, which is highly enriched in HSC and capable of BM reconstitution in lethally irradiated mice (Guo et al., 2003) , should not have failed to demonstrate terminal neuronal differentiation. Additionally, with respect to purity and homogeneity of the transplanted cells obtained from BM-SP (Castro et al., 2002) or Sca-1 ϩ , ckit ϩ , lin Ϫ BM (Koda et al., 2005; Koshizuka et al., 2004) , these cells should yield similar results. However, the results of these three studies are quite disparate. In contrast to Sca-1 ϩ , c-kit ϩ , lin Ϫ -derived oligodendrocytes and astrocytes in the compression-injured animals, there was no indication of a SP-mediated neural differentiation in the irradiated recipient group. Does that mean heterogeneous HSC subpopulations differ in their ability to cross the germ layer restriction or does the animal model drive the terminal fate of the graft? While this question cannot at present be answered, it is apparent that within a given graft (always a heterogeneous BM cell population), the injured host spinal microenvironment dictates the fate of the transplant.
Both demyelination and compression lesions favor mainly Schwann cell and oligodendrocyte differentiation (Akiyama et al., 2002a; Koshizuka et al., 2004; Sasaki et al., 2001) . In contrast, terminal differentiation of stem cells placed in the irradiated spinal cord appears to respond in a dose-dependent manner. For example, sublethal host irradiation facilitates a mixed microglial/astroglial/neuronal phenotype of engrafted cells (Corti et al., 2002) , whereas lethal irradiation does not appear to provide differentiation cues at all (Castro et al., 2002) . Regardless of whether BM was applied intravenously or intraspinally after a EB lesion (Akiyama et al., 2002a; Sasaki et al., 2001) , ultra-structural analyses revealed an extensive remyelination throughout the dorsal funiculus. In these studies, the transplant-specific marker (LacZ) clearly co-localized with some Schwann cell-and oligodendrocyte-like cells leading to the conclusions that (1) at least a portion of the myelinating cells originate from the BM and (2) their route of delivery does not affect their differentiation pattern. Importantly, the morphology of the remyelinated axons was reminiscent of both peripheral and central myelin. It is unlikely that adjacent nerve roots are a source for the myelinating cells as no remyelination was observed in control lesions without cells or after systemic application of Schwann cells (Akiyama et al., 2002a) . One important point is that both studies were conducted in the same laboratory and thus results await independent replication. In the absence of data indicating the mechanism underlying these findings, one needs to be cautious before overestimating the potential of BM to cross germ layer restrictions. Nonetheless, an intriguing and critical question arising from these results is what specific cell type within the BM is capable of remyelinating axons.
Ficoll-separated BM yields a mononuclear cell fraction that includes diverse HSCs, tissue-specific progenitor cells, stromal cells, and a variety of highly specialized blood cells in different stages of development (Herzog et al., 2003) . Although HSCs were present in all transplantation paradigms, only whole BM appears to have the capacity to induce remyelination. It is unclear if this regenerative response is directly attributable to a cellular substrate or rather the result of the secretion of yet undescribed factors that trigger an endogenous response. By using a non-defined heterogeneous BM population there is always the possibility of contamination by non-hematopoietic stem cells. Recent studies have suggested that BM serves as a "hideout" for early tissuecommitted stem cells (Kucia et al., 2005) , which com-ENZMANN ET AL.
plicates a conclusive interpretation of in vivo findings after BM transplantation. Alternatively, based on the fact that HSCs might have the potential to form ectodermal tissue, transplanted cells may have been utilized by the host to reconstitute the BM following irradiation, which could lead to the exhaustion of the engrafted circulation pool. This could contribute to the limited neural transdifferentiation observed in these studies. Thus, applying purified HSC into a focal lesion using the same experimental paradigms that permitted the forming of oligodendrocyte-like cells, might answer the question whether the grafted cells or the kind of lesion are crucial for the differentiated phenotype. Adding to the complexity of these studies is the fact that even seemingly pure hematopoietic stem cells are heterogeneous (Shizuru et al., 2005) . These issues need to be resolved before BM can be considered as a therapeutic treatment for SCI.
Another problematic issue with respect to the interpretation of these studies lies in the fact that only two of the above-cited articles assessed the functional outcome after BM transplantation. In one case, in vitro field potential recording revealed that the conduction velocity in BM-recipients was significantly faster than in the control group (Akiyama et al., 2002a) . Applying their own hindlimb motor function score, Koshizuka et al. (2004) found significant partial hindlimb weight support in mice that had been transplanted with HSCs. The latter finding might be attributable to a secretion of trophic factors rather than graft differentiation, as both the small number and phenotype of the engrafted cells (no mature myelinating cells) cannot account for the functional improvement. Despite apparent functional benefit after BM transplantation in SCI, we suggest a need for a more stringent approach to unambiguously define the capability of BM-derived cells to override germ layer restrictions. Considering the heterogeneity of the population of transplanted cells, their application modus, and recipient models, further evaluation is imperative to determine whether BM has the potential to differentiate into non-hematopoietic tissue.
BONE MARROW STROMAL CELL TRANSPLANTATION IN SCI
Bone marrow stromal cells (BMSCs) represent a heterogeneous cell population, with perhaps the greatest diversity of cell types present in the transplantation fraction than either BM or HSCs. Further complicating their use, there exists neither a standardized protocol for culture conditions nor any commonly accepted set of phenotypic markers (Pittenger et al., 1999) to characterize them. BMSCs are isolated by their affinity to attach to uncoated plastic dishes and are cultured in the presence of serum for different lengths of time, undoubtedly resulting in isolation and expansion of highly distinct cells specific to the laboratory in which they are derived. Considering this, the observed beneficial effects on the functional recovery after BMSC transplantation into the injured spinal cord are surprisingly homogeneous. In all cases where functional outcome was assessed, typically employing the BBB open-field test (Basso et al., 1995) , significant improvement in locomotor behavior was observed either in the absence (Lu et al., 2005; Neuhuber et al., 2005; Ohta et al., 2004; Wu et al., 2003) or presence (Akiyama et al., 2002b; Chopp et al., 2000; Hofstetter et al., 2002; Zhao et al., 2004; Zurita and Vaquero, 2004) of neurally differentiated grafts. While in principle BBB scoring is standardized and reproducible, it is subjective (e.g., rater-dependent) and a non-linear scale (Ferguson et al., 2004; Koopmans et al., 2005; Scheff et al., 2002) . Ultimately, resolution of the functional consequences of all stem cell grafts will be better evaluated with more sensitive and objective quantitative measures such as kinematic (Ribotta et al., 1998; Thota et al., 2005) or electrophysiological (Imaizumi et al., 1998; Loy et al., 2002) analyses.
Applying more stringent and injury-relevant locomotor tests, Lu et al. (2005) and Neuhuber et al. (2005) observed neither trans-differentiation of BMSCs nor improvement of forelimb function after engraftment into a dorsal hemisection lesion. Histological analysis of the transplanted BMSC graft revealed the diversity of their fate. Scattered cells expressing NeuN (Chopp et al., 2000; Deng et al., 2005; Hofstetter et al., 2002) or GFAP (Lee et al., 2003; Zurita et al., 2004) were found throughout the contused host spinal parenchyma. However, the most important feature was not their differentiated phenotype but their capacity to align and form cell bundles bridging the lesion epicenter (Hofstetter et al., 2002; Wu et al., 2003; Zurita et al., 2004) . This property is not unique to BMSC as modified radial glial act similarly in the contused spinal cord (Hasegawa et al., 2004) . Even though the numbers of engrafted BMSCs gradually decreased over time post-transplantation, the animals were left with smaller tissue cavities compared to controls (Ohta et al., 2004; Wu et al., 2003) , indicating possible secretion of ameliorative trophic factors by the engrafted cells. In support of this possibility, recent publications have documented that BMSCs are capable of constitutively secreting a variety of cytokines such as IL-6, MCP, SCF, and SDF-1, and growth factors such as BDNF, VEGF (Neuhuber et al., 2005) , NGF, NT-3 (Lu et al., 2005) , and brain natriuretic peptide (Song et al., 2004) , which could potentially contribute to the function improvement seen after the grafting in the injured spinal cord. Neuhu-STEM CELL TRANSPLANTATION THERAPY FOR SPINAL CORD REPAIR ber et al. (2005) detected axonal growth in a BMSC donor-dependent manner; BMSC from different donors expressed different levels of growth factors and cytokines. Additionally, Lu et al. (2005) found increased numbers of axons penetrating BDNF-expressing BMSCs compared to unaltered grafts, further indicating the importance of this growth factor in graft-induced regenerative responses in the injured spinal cord.
While BMSCs might be used as a transient scaffold or vehicle for trophic factor delivery in SCI, present data do not support their utility in cellular replacement approaches. This conclusion is largely supported by results demonstrating the failure of engrafted BMSCs to terminally differentiate into therapeutically relevant neural phenotypes. The one documented exception would be grafting into the glial-depleted, EB-lesioned spinal cord, where Schwann cell-like graft differentiation has been observed with BMSC (Akiyama et al., 2002b) . However, this terminal phenotype may be more reflective of the lesion environment than the grafted cell type (Blakemore, 2005) .
UMBILICAL CORD BLOOD CELL TRANSPLANTATION IN SCI
Comparable to BM, umbilical cord blood (UCB) is a heterogeneous population of cells enriched in HSC but displaying a higher proliferative capacity (Mayani and Lansdorp, 1998) . To date, three reports have utilized UCB cells in SCI. Unfortunately, the variability in all experimental parameters makes a thorough analysis difficult. Xenografts of either human UCB CD34 ϩ cells or a commercial available cell line (no details available) resulted in an improvement of function with no (Saporta et al., 2003) or less pronounced graft differentiation (Kuh et al., 2005; Zhao et al., 2004) . The sparse astrocytic differentiation in the latter experiment is unlikely to be solely responsible for the observed behavioral improvement, and the question remains about what mechanism underlies these observations. As UCB cells are seen as an alternative source of HSCs, these data should be evaluated parallel to the studies that employed BM in SCI. It is impossible to relate functional improvement to any specific donor cell when heterogeneous populations of UCB have been used. More thorough experiments are needed to evaluate how UCB modulates improvement after SCI and whether it possesses the potential of tissue plasticity.
CONCLUSION
Given the above discussion, what are the prospects for stem cell therapy in the treatment of SCI? To answer that question, it is necessary to first consider what the likely targets for stem cell therapy are. Treatment of SCI will ultimately require restriction of secondary cell death, regeneration of severed axons, remyelination of demyelinated and/or regenerating axons, and/or neuronal replacement. Of those, remyelination is the "low-hanging fruit" for stem cell repair. There are a substantial number of chronically demyelinated axons after both experimental animal (Blight, 2002; Cao et al., 2002a,b; Talbott et al., 2005) and human (Alexeeva et al., 1998; Guest et al., 2005) SCI. As discussed above, engrafted stem cells are competent to remyelinate those axons in a dys/demyelinated SCI paradigm but not following a traumatic insult. The extent to which they remyelinate is low and must be improved if this is to be a successful therapeutic approach. Moreover, as we further discussed, combinatorial strategies will be necessary for optimal functional return. Stem cells are likely to be therapeutically valuable both in providing permissive substrates for axonal regeneration as well as "cellular minipumps" delivering trophic factors that would result in enhanced white matter sparing and/or axonal regeneration. However, the specific mechanism through which this latter effect has been shown to be beneficial in experimental SCI has yet to be elucidated, making it difficult to predict how effective this approach would be in the treatment of human SCI. By far, the most difficult area of repair for engrafted stem cells would be neuronal replacement. This requires not only ensuring that the stem cells differentiate into the correct types of neurons, but also that they form correct efferent and afferent connections. This may prove possible with local intraspinal circuitry, but is a daunting prospect for long projection neurons.
With respect to the optimal type of stem cell that should first be tried clinically, we believe that at present ES cells hold the greatest promise. They are clonal, can be expanded indefinitely, can be induced along specific lineages, and are readily amenable to genetic manipulation. The downside of ES cells is the fact that these would be allogeneic grafts and there are obvious ethical concerns (Ruse and Pynes, 2003; Smith and Cohen, 2003) . Ultimately, peripheral autologous stem cells would be the ideal graft source, as they would be readily accessable and eliminate immunological concerns. However, until it is determined whether transdifferentiation is indeed possible along desired lineages and we better understand the molecular mechanism underlying that phenomenon, the use of non-neural stem cells will be restricted to applications where cell-specific differentiation is not a desired component of the therapeutic treatment.
Lastly, the issue of how fast to proceed is constantly debated. There are some in the SCI research community who believe that this is such a devastating disease that ENZMANN ET AL.
we have to move forward to clinical trials even if there is not as much pre-clinical data to unequivocally predict success. Others, including ourselves, believe that present preclinical data cautions against moving too quickly, doing additional harm would be catastrophic (Anderson et al., 2005) . This issue is ultimately a personal choice between physician and patient and a choice that hopefully will be made very carefully on both sides.
